CEO & Co-Founder of PanTher Therapeutics
Laura Indolfi, PhD, is the Chief Executive Officer and Co-Founder of PanTher Therapeutics, a clinical-stage oncology company developing innovative cancer treatment solutions that enable localized treatment and continuous dosing of cancer therapy at the site of a tumor, without the unwanted side effects of systemic drug treatment. Based on foundational technology she invented in the labs at Massachusetts Institute of Technology (MIT) and Harvard Medical School, she has led PanTher’s business and scientific progress to create its proprietary Sagittari™ platform, a revolutionary technology for the local administration of cancer therapeutics to treat solid tumors. Under her leadership, the company has advanced its lead drug candidate, PTM-101, from preclinical R&D studies, to scale-up of manufacturing, to clinical trials for the treatment of pancreatic cancer. Dr. Indolfi has raised equity and grant funding for PanTher since its inception in 2016 and built an experienced leadership team to guide the company’s success.
Dr. Indolfi has been recognized for her entrepreneurial accomplishments by being named a TED Fellow, one of 21 people chosen annually as the most disruptive and transformative change-makers in the world. In addition, she was invited to be an attendee at the “Fortune: Most Powerful Women – Next Gen” summit and she was one of five women selected for the inaugural class in 2018 of the MassNextGen program, honoring exceptional leaders in the biotech industry. Prior to founding PanTher Therapeutics, Dr. Indolfi was a postdoctoral associate at the Harvard-MIT Institute for Medical Engineering and Science and served as an entrepreneur-in-residence at the Massachusetts General Hospital Cancer Center. She holds a PhD in Biomaterials and MS and BS degrees in Materials Science and Engineering from the University of Naples Federico II in Italy.
https://www.panthertx.com/
Company
LinkedIn
Personal
LinkedIn
Location: Boston, USA
